Original ContributionsDistinction Between Endometrial and Endocervical Adenocarcinoma: An Immunohistochemical StudyCastrillon, Diego H. M.D., Ph.D.; Lee, Kenneth R. M.D.; Nucci, Marisa R. M.D.Author Information From the Women's and Perinatal Pathology Division, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Presented at the 1999 USCAP meeting. Address correspondence and reprint requests to Marisa R. Nucci, M.D., Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115. International Journal of Gynecological Pathology: January 2002 - Volume 21 - Issue 1 - p 4-10 Buy Abstract We investigated the possibility of distinguishing between primary endometrial and endocervical adenocarcinomas by using a panel of immunohistochemical stains, which included vimentin (VIM), carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), and cytokeratins 7 and 20 (CK7 and CK20). Twenty-nine endocervical adenocarcinomas (CCAs) and 30 endometrial adenocarcinomas (EMCAs) including cases with overlapping histologic features (CCAs with endometrioid differentiation [15/29] and EMCAs with mucinous differentiation [16/30]) were evaluated. Most EMCAs (29/30, 97%) were VIM positive, whereas only 2/29 (7%) CCAs were VIM positive. The great majority of EMCAs (28/30) and all 29 CCAs were CK7 positive, whereas all 30 EMCAs and 27/29 CCAs were negative for CK20. CEA positivity was more common in CCAs (18/29, 62%) than in EMCAs (8/30, 27%). EMA positivity was present in all 30 EMCAs and in 26 of 29 (90%) CCAs. We conclude that VIM and CEA are useful immunohistochemical markers in distinguishing EMCAs and CCAs, but CK7, CK20, and EMA are not useful in this distinction. © 2002 Lippincott Williams & Wilkins, Inc.